Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition

[1]  C. Drake,et al.  Immunotherapy for Prostate Cancer. , 2018, Cold Spring Harbor perspectives in medicine.

[2]  D. Bentrem,et al.  Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells , 2018, Scientific Reports.

[3]  C. Drake,et al.  Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks , 2018, Current Oncology Reports.

[4]  C. Drake,et al.  Inhibitors of the PD-1 Pathway in Tumor Therapy , 2018, The Journal of Immunology.

[5]  C. Drake,et al.  Immunotherapy for Prostate Cancer: An Evolving Landscape , 2018 .

[6]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[7]  J. Li,et al.  TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways , 2018, Cell Death & Disease.

[8]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[9]  C. Drake,et al.  Combining Intra-Tumoral Treg Depletion with Androgen Deprivation Therapy (ADT): Pre-Clinical Activity in the Myc-CaP Model , 2017, Prostate Cancer and Prostatic Diseases.

[10]  C. Drake,et al.  Myeloid‐derived cells in prostate cancer progression: phenotype and prospective therapies , 2017, Journal of leukocyte biology.

[11]  Christopher J. Ott,et al.  BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1 , 2017, Cell reports.

[12]  Jun Luo,et al.  Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer , 2016, The oncologist.

[13]  Benjamin G. Bitler,et al.  BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. , 2016, Cell reports.

[14]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[15]  J. Taube,et al.  The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder , 2016, Oncoimmunology.

[16]  C. Graham,et al.  A primer on tumour immunology and prostate cancer immunotherapy. , 2016, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[17]  Yong-Chen Lu,et al.  Cancer immunotherapy targeting neoantigens. , 2016, Seminars in immunology.

[18]  Nita Ahuja,et al.  Epigenetic Therapeutics: A New Weapon in the War Against Cancer. , 2016, Annual review of medicine.

[19]  C. Drake,et al.  New Strategies in Bladder Cancer: A Second Coming for Immunotherapy , 2015, Clinical Cancer Research.

[20]  M. Scott Lucia,et al.  Paucity of PD-L1 Expression in Prostate Cancer: Innate and Adaptive Immune Resistance , 2015, Prostate Cancer and Prostatic Disease.

[21]  B. Kwon.  Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses? , 2015, Immune network.

[22]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[23]  J. Powell,et al.  A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy , 2015, Computational and structural biotechnology journal.

[24]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[25]  R. Foley,et al.  Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens , 2014, Front. Immunol..

[26]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[27]  S. Knapp,et al.  RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain , 2013, Proceedings of the National Academy of Sciences.

[28]  Claudia C. Preston,et al.  The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer , 2013, PloS one.

[29]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[30]  G. Sauter,et al.  High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. , 2013, European journal of cancer.

[31]  C. Drake,et al.  Immunotherapy earns its spot in the ranks of cancer therapy , 2012, The Journal of experimental medicine.

[32]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[33]  M. Ares,et al.  Purification of RNA using TRIzol (TRI reagent). , 2010, Cold Spring Harbor protocols.

[34]  M. Karin,et al.  B-cell-derived lymphotoxin promotes castration-resistant prostate cancer , 2010, Nature.

[35]  B. Seliger,et al.  Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer , 2010, Cancer Immunology, Immunotherapy.

[36]  A. Battistini,et al.  IRF‐7 , 2007, Annals of the New York Academy of Sciences.

[37]  Hidde L. Ploegh,et al.  Antigen Presentation and the Ubiquitin‐Proteasome System in Host–Pathogen Interactions , 2006, Advances in Immunology.

[38]  C. Sawyers,et al.  Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. , 2005, Cancer research.

[39]  J. Brady,et al.  The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. , 2005, Molecular cell.

[40]  Qiang Zhou,et al.  Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. , 2005, Molecular cell.

[41]  C. Korch,et al.  Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.

[42]  Tom Misteli,et al.  The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Davidr . Johnson.  Locus-Specific Constitutive and Cytokine-Induced HLA Class I Gene Expression 1 , 2003, The Journal of Immunology.

[44]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[45]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[46]  C. Kurts,et al.  Characterization of the ovalbumin‐specific TCR transgenic line OT‐I: MHC elements for positive and negative selection , 2000, Immunology and cell biology.

[47]  D. Johnson.  Differential expression of human major histocompatibility class I loci: HLA-A, -B, and -C. , 2000, Human immunology.

[48]  R. Young,et al.  Transcription of eukaryotic protein-coding genes. , 2000, Annual review of genetics.

[49]  Paul J Hertzog,et al.  SOCS1 Is a Critical Inhibitor of Interferon γ Signaling and Prevents the Potentially Fatal Neonatal Actions of this Cytokine , 1999, Cell.

[50]  B. Peterlin,et al.  The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. , 1997, Nucleic acids research.

[51]  K. Ozato,et al.  Induction of MHC class I expression by the MHC class II transactivator CIITA. , 1997, Immunity.

[52]  P. Stern,et al.  Loss of HLA class I expression in prostate cancer: implications for immunotherapy. , 1995, Urology.